Targeting CGRP in migraine: a matter of choice and dose

Lancet Neurol. 2020 Sep;19(9):712-713. doi: 10.1016/S1474-4422(20)30282-9.

Authors

Linda Al-Hassany¹, Antoinette Maassen Van Den Brink²

Affiliations

¹ Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands.
² Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands. Electronic address: a.vanharen-maassenvandenbrink@erasmusmc.nl.

PMID: 32822621
DOI: 10.1016/S1474-4422(20)30282-9

No abstract available

Publication types

Comment

MeSH terms

Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide*
Double-Blind Method
Humans
Migraine Disorders*

Substances

Calcitonin Gene-Related Peptide Receptor Antagonists
Calcitonin Gene-Related Peptide